Cervical cancer constitutes a leading cause of morbidity and cancer deaths in women
throughout the world. Approximately two thirds of the patients are diagnosed with locally …

Cervical cancer represents the third most common cause of female cancer mortality. Even
with the best currently available treatment, a significant proportion of patients will experience …

Background Vascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator
of disease progression in cervical cancer. Bevacizumab, a humanized anti-VEGF …

Cervical cancer is the third most commonly diagnosed cancer worldwide and the fourth
leading cause of cancer death in women. Major advances but still insufficient achievements …

Vascular endothelial growth factor (VEGF) has emerged as a therapeutic target in several
malignancies, including cervical cancer. Chemotherapy doublets combined with the fully …

Cervical cancer is the third most common cancer worldwide, and the development of new
diagnosis, prognostic, and treatment strategies is a major interest for public health. Cisplatin …

Objective Adding bevacizumab to cisplatin–paclitaxel for advanced cervical cancer
significantly improves overall and progression-free survival. We evaluated bevacizumab …

Patients with advanced stage or recurrent cervical cancer represent a population with limited
chemotherapeutic options. More specifically, patients with recurrent disease have a poor …

Summary Background On Aug 14, 2014, the US Food and Drug Administration approved the
antiangiogenesis drug bevacizumab for women with advanced cervical cancer on the basis …

Effective cytotoxic treatment options for advanced cervical cancer are exceedingly limited.
Cisplatin-based combination chemotherapy, the most commonly used cytotoxic therapy, has …